Clinical trials: Multiple Sclerosis Relapse
Anxiety
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
It is a multicentric randomized and controlled study comparing a Scheme therapy program versus local practice in RRMS patients with anxiety.
- Trial name
- NCT04030819
- Testing
- schema therapy
- Where
- France
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Paris Nanterre University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no…
- Trial name
- NCT05028634
- Testing
- Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
- Where
- 33 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Celgene
Multiple Sclerosis
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
The primary objective was to estimate the tolerability and safety of 2 doses of Teriflunomide administered once daily for 24 weeks, compared to placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable…
- Trial name
- NCT00475865
- Testing
- Teriflunomide, Glatiramer Acetate (GA)
- Where
- 6 sites in United States, Austria and 4 more
- Volunteers
- 123 people
- Sponsor
- Sanofi
Multiple Sclerosis
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered…
- Trial name
- OSSIA (NCT07609719)
- Testing
- OCR SC
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
The Electronic Device - The RebiSmart™ is an electronic injection device that is being studied for the delivery of Merck Serono's Rebif® New Formulation.
- Trial name
- NCT00735007
- Testing
- Rebif® New Formulation (RNF) using RebiSmartTM
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-remitting
Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis
This is a research study. The investigators are inviting participants to participate in this research study between the ages of 18-45, who have stable Relapsing-Remitting Multiple Sclerosis (RRMS), are able to walk 25 ft…
- Trial name
- NCT02687919
- Testing
- Modified Paleo diet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Amanda Irish
Multiple Sclerosis, Relapsing-Remitting
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
The purpose of this study is to assess the impact of Natalizumab (Tysabri) therapy on sleep efficiency, total sleep time and sleep latency, in Multiple Sclerosis (MS) patients receiving Natalizumab for 6 months relative to…
- Trial name
- NCT01591551
- Testing
- Natalizumab (Tysabri)
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Cornerstone Health Care, PA
Multiple Sclerosis, Relapsing-Remitting
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve…
- Trial name
- MS-HDtDCS (NCT05958381)
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The University of Texas at Dallas
Multiple Sclerosis, Relapsing-Remitting
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus…
- Trial name
- INCREASE (NCT03387046)
- Testing
- D-aspartate, IFN beta-1a, Methylprednisolone
- Where
- 17 sites in Italy
- Volunteers
- 7 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
- Trial name
- ZENITH (NCT07224373)
- Testing
- AZD0120 - Regimen 1, AZD0120 - Regimen 2
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS
The purpose of the study is to determine whether giving intravenous dexamethasone every 4 weeks during the first 12 months of weekly Avonex dosing will reduce the progression of functional impairment, brain atrophy, relapse rate…
- Trial name
- NCT00232193
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Providence Multiple Sclerosis Center
Multiple Sclerosis
A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple Sclerosis
This study is an open-label, single-arm, run-in study in patients with RRMS treated with first line therapies (interferon-beta, glatiramer acetate, teriflunomide and dimethyl fumarate), assessing the feasibility and tolerability…
- Trial name
- FAST-MS (NCT06039007)
- Testing
- 7-day Fasting-Mimicking Diet (7-DAY FMD)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Ospedale Policlinico San Martino
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Scientific background: Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
- Trial name
- NCT00220493
- Testing
- Ritalin
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center
Multiple Sclerosis
Natalizumab High Titer Immunogenicity and Safety
The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with…
- Trial name
- NCT00516893
- Testing
- BG00002-E (natalizumab high titer)
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Biogen
Relapsing Forms of MS
Study of Diroximel Fumarate in the Real-World Setting
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- NCT04746976
- Testing
- Diroximel Fumarate
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Fingolimod Effect on Cytokine and Chemokine Levels
The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses.
- Trial name
- NCT02373098
- Testing
- Fingolimod 0.5 mg
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.
- Trial name
- ALITHIOS (NCT03650114)
- Testing
- Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV)
- Where
- 295 sites in United States, Argentina and 35 more
- Volunteers
- 1,882 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS) - Relapsing-remitting, Anxiety
Psychological Interventions for Multiple Sclerosis: Effects on Anxiety, Depression, and Cognition.
This study evaluated the efficacy of two structured psychological interventions in individuals with relapsing-remitting multiple sclerosis (RRMS).
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Anxiety, Depression, Cognitive Impairment
- Trial name
- MS-PSY (NCT07273604)
- Testing
- Cognitive Behavioral Therapy (CBT), Psychophysiological Regulation Therapy (PRT)
- Where
- Spain
- Volunteers
- 148 people
- Sponsor
- Moisés Bermúdez Hernández